×

Methods of determining dose of IL-31 agonist to treat pulmonary inflammation

  • US 8,029,775 B2
  • Filed: 08/26/2010
  • Issued: 10/04/2011
  • Est. Priority Date: 01/10/2007
  • Status: Active Grant
First Claim
Patent Images

1. A method for determining the optimum dose of an IL-31 agonist to treat asthma, airway hyper-responsiveness or allergic rhinitis comprising:

  • a) taking a first sample of lung tissue or BAL fluid from a patient with asthma, airway hyper-responsiveness or allergic rhinitis;

    b) measuring the level of proinflammatory cytokines expressed in the first sample;

    c) administering an amount of the IL-31 agonist to the patient, wherein the IL-31 agonist is a polypeptide comprising amino acid residues 27-164 of SEQ ID NO;

    2;

    d) taking a second sample of lung tissue or BAL fluid from the patient;

    e) measuring the level of proinflammatory cytokines expressed in the second sample;

    f) comparing the level of proinflammatory cytokines expressed in the first sample to the level of proinflammatory cytokines expressed in the second sample; and

    g) determining the level of the IL-31 agonist that is sufficient to reduce the level of proinflammatory cytokines in the second sample.

View all claims
  • 0 Assignments
Timeline View
Assignment View
    ×
    ×